Neoadjuvant chemotherapy: a new criterion for selection of candidate patients for surgery of low tumour burden metastases from malignant melanoma?

Abstract

Neoadjuvant chemotherapy can be considered as a new criterion for better selection of candidate patients for lung metastasis surgical resection. This would also avoid useless surgical procedures in rapidly progressive disease and give information on the chemosensibility of the metastatic disease. This study needs further confirmation, particularly with chemotherapy regimens that have demonstrated better objective responses.

Neoadjuvant treatment of melanoma: case reports and review

“…Since the comparison variable was surgical resection versus no resection, no inference can be made about the utility of neoadjuvant approach. Jouary et al reported their single institution retrospective review of single agent DTIC in the neoadjuvant setting for melanoma pulmonary metastases [ 6 ]. In their cohort of 13 patients, they observed a median survival of 31.6 months versus 25.3 months in the no neoadjuvant group.…”